Partial Return of Executive Compensation

Osaka, Japan, May 12, 2010 ---- Mitsubishi Tanabe Pharma Corporation (President & CEO, Michihiro Tsuchiya) announced today that the Company has determined a partial return of executive compensation.

On April 13, 2010, Mitsubishi Tanabe Pharma and its subsidiary Bipha Corporation received an administrative action, suspension of business and an order for improvement from the Ministry of Health, Labour and Welfare in regard to a violation of the Pharmaceutical Affairs Act as for Medway Injection, a recombinant human serum albumin preparation. Taking this administrative action very seriously the Company decided that some executive compensation will be returned as a means of clarifying its social responsibilities.

The Company will take measures promptly to prevent a recurrence, and do its utmost to regain the trust of society.

In addition, Corporate Auditors have proposed to voluntarily return some auditor's compensation.

1. Details of the return of compensation

President & Representative Director, and	To return 50% of the value of monthly compensation
Representative Director & Executive Vice President	
Other Directors, and Managing Executive Officers	To return 30% of the value of monthly compensation
Other Executive Officers	To return 10% of the value of monthly compensation

2. Period for the return of compensation

From May 2010, for the mean time

⟨⟨For Details, Contact the Following Section⟩⟩

Corporate Communications Dept., Mitsubishi Tanabe Pharma Corporation

Tel +81-6-6205-5211